DARRT 1 (NOX66-002A)


    NOX66 and Palliative Radiotherapy in Patients with Late-Stage Prostate Cancer – a Phase 1b Proof of Concept and Dose confirmation study.
    Phase of study I
    Patient population Males with late stage metastatic castrate resistant cancer of the prostate
    Number of patients 24

    To combine NOX66 with palliative (low dose, short duration) radiotherapy to determine:

    • Safety of 3 different doses of NOX66
    • The appropriate dose of NOX66 for use in combination with palliative radiotherapy
    • Signals of efficacy to support design of further studies of NOX66 in combination with palliative radiotherapy in patients with solid tumours
    Locations Australia – NSW: Newcastle, Crows Nest, Tamworth, Orange; Queensland: Southport
    New Zealand – Christchurch
    Georgia - Tbilisi
    STATUS Currently Enrolling patients
    Clinical trial details https://www.clinicaltrials.gov/ct2/show/NCT03307629?term
    Contact for information medical.information@noxopharm.com